Literature DB >> 8106860

Sequence variation within the human immunodeficiency virus V3 loop at seroconversion.

M Ait-Khaled1, V C Emery.   

Abstract

Analysis of the HIV-1 V3 quasispecies present in an individual at the time of seroconversion was carried out. The polymerase chain reaction (PCR) was used to amplify proviral HIV-1 DNA extracted from peripheral blood mononuclear cells from a patient who was viraemic (p24 = 15 pg/ml) and had an equivocal HIV-1 antibody status. The PCR products were cloned and the DNA sequence determined for 15 clones. These data showed that the V3 region contained only limited sequence heterogeneity with a major variant accounting for 66% of the protein quasispecies present. The protein sequence of the principal neutralising domain on all species contained the relatively rare GPGKTL motif rather than GPGRAF. The relevance of these data for early stages of HIV infection are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106860     DOI: 10.1002/jmv.1890410403

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Genetically related human immunodeficiency virus type 1 in three adults of a family with no identified risk factor for intrafamilial transmission.

Authors:  L Bélec; A Si Mohamed; M C Müller-Trutwin; J Gilquin; L Gutmann; M Safar; F Barré-Sinoussi; M D Kazatchkine
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

2.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Authors:  J Lewis; P Balfe; C Arnold; S Kaye; R S Tedder; J A McKeating
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.